LY-272015 is a beta-carboline derivative drug developed by Eli Lilly which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models and is also used in research into the other functions of the 5-HT2B receptor.
This page contains content from the copyrighted Wikipedia article "LY-272015"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
